Provided by Tiger Fintech (Singapore) Pte. Ltd.

VYNE Therapeutics Inc.

1.41
-0.0300-2.08%
Post-market: 1.410.00000.00%16:00 EDT
Volume:162.07K
Turnover:229.89K
Market Cap:20.91M
PE:-1.51
High:1.50
Open:1.42
Low:1.37
Close:1.44
Loading ...

Company Profile

Company Name:
VYNE Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
13
Office Location:
685 Route 202/206 N,Suite 301,Bridgewater,New Jersey,United States
Zip Code:
08807
Fax:
- -
Introduction:
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Directors

Name
Position
David Domzalski
President, Chief Executive Officer and Director
Patrick LePore
Lead Independent Director
Anthony Bruno
Director
Elisabeth Sandoval
Director
Sharon Barbari
Director
Steven Basta
Director

Shareholders

Name
Position
David Domzalski
President, Chief Executive Officer and Director
Tyler Zeronda
Chief Financial Officer and Treasurer
Iain Stuart
Chief Scientific Officer
Mutya Harsch
General Counsel, Chief Legal Officer and Secretary